Study of Novel Treatment Combinations in Patients With Lung Cancer
Running, not enrolling · Phase 2
Conditions studied: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
In brief
The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Key facts
- Study ID
- NCT05633667
- Run by
- Gilead Sciences
- People needed
- 192
- Starts
- 2023-03-16
- Expected to finish
- 2029-09-01
- Last updated by the study team
- 2026-06-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fort Wayne Medical Oncology and Hematology, Inc.,Substudy-03 — Fort Wayne, Indiana, United States
- Baptist Health Lexington,Substudy-03 — Lexington, Kentucky, United States
- Washington University School of Medicine - Siteman Cancer Center,Substudy-01 — St Louis, Missouri, United States
- Washington University School of Medicine - Siteman Cancer Center,Substudy-02 — St Louis, Missouri, United States
- Washington University School of Medicine - Siteman Cancer Center,Substudy-03 — St Louis, Missouri, United States
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri, United States
- Oncology Hematology Care Clinical Trials, LLC,Substudy-01 — Cincinnati, Ohio, United States
- Oncology Hematology Care Clinical Trials, LLC,Substudy-02 — Cincinnati, Ohio, United States
- Oncology Associates of Oregon, PC,Substudy-01 — Eugene, Oregon, United States
- Oncology Associates of Oregon, PC,Substudy-02 — Eugene, Oregon, United States
- Fundação Pio XII - Hospital de Amor,Substudy-01 — Barretos, Brazil
- Centro Gaúcho Integrado de Oncologia Hematologia, Ensino e Pesquisa Ltda./Hospital Mãe de Deus,Substudy-03 — Porto Alegre, Brazil
- Hospital Mae de Deus,Substudy-01 — Porto Alegre, Brazil
- Hospital Mae de Deus — Porto Alegre, Brazil
- Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-01 — Porto Alegre, Brazil
- Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03 — Porto Alegre, Brazil
- BP-A Beneficencia Portuguesa De Sao Paulo,Substudy-01 — São Paulo, Brazil
- Fundação Antonio Prudente - Hospital do Câncer AC Camargo,Substudy-01 — São Paulo, Brazil
- Fundação Antonio Prudente/A.C. Camargo Cancer Center,Substudy-03 — São Paulo, Brazil
- Real e Benemérita Associação Portuguesa de Beneficência/Hospital Beneficência Portuguesa de São Paulo (Hospital BP),Substudy-03 — São Paulo, Brazil
- Queen Mary Hospital,Substudy-01 — Hong Kong, Hong Kong
- Queen Mary Hospital,Substudy-02 — Hong Kong, Hong Kong
- Queen Elizabeth Hospital,Substudy-01 — Hong Kong, Hong Kong
- Queen Elizabeth Hospital,Substudy-02 — Hong Kong, Hong Kong
- Arizona Oncology Associates,Substudy-02 — Tucson, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.